Mega Lifesciences Public Stock Working Capital
| MEGA Stock | THB 34.75 0.50 1.42% |
Mega Lifesciences Public fundamentals help investors to digest information that contributes to Mega Lifesciences' financial success or failures. It also enables traders to predict the movement of Mega Stock. The fundamental analysis module provides a way to measure Mega Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mega Lifesciences stock.
Mega |
Mega Lifesciences Public Company Working Capital Analysis
Mega Lifesciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Mega Lifesciences Working Capital | 3.15 B |
Most of Mega Lifesciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mega Lifesciences Public is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Mega Lifesciences Public has a Working Capital of 3.15 B. This is much higher than that of the Pharmaceuticals sector and 54.66% lower than that of the Health Care industry. The working capital for all Thailand stocks is 113.24% lower than that of the firm.
Mega Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mega Lifesciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mega Lifesciences could also be used in its relative valuation, which is a method of valuing Mega Lifesciences by comparing valuation metrics of similar companies.Mega Lifesciences is currently under evaluation in working capital category among its peers.
Mega Fundamentals
| Return On Equity | 0.29 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 38.59 B | |||
| Shares Outstanding | 871.87 M | |||
| Shares Owned By Insiders | 60.85 % | |||
| Shares Owned By Institutions | 7.67 % | |||
| Price To Book | 4.70 X | |||
| Price To Sales | 2.68 X | |||
| Revenue | 14.14 B | |||
| Gross Profit | 5.95 B | |||
| EBITDA | 2.58 B | |||
| Net Income | 1.95 B | |||
| Cash And Equivalents | 1.42 B | |||
| Cash Per Share | 1.63 X | |||
| Total Debt | 1.23 B | |||
| Debt To Equity | 21.10 % | |||
| Current Ratio | 1.70 X | |||
| Book Value Per Share | 9.78 X | |||
| Cash Flow From Operations | 2.73 B | |||
| Earnings Per Share | 2.68 X | |||
| Price To Earnings To Growth | 21.52 X | |||
| Target Price | 55.36 | |||
| Number Of Employees | 21 | |||
| Beta | 0.56 | |||
| Market Capitalization | 42.72 B | |||
| Total Asset | 13.27 B | |||
| Retained Earnings | 2.03 B | |||
| Working Capital | 3.15 B | |||
| Current Asset | 5.87 B | |||
| Current Liabilities | 2.72 B | |||
| Z Score | 21.4 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 1.93 % | |||
| Net Asset | 13.27 B | |||
| Last Dividend Paid | 1.61 |
About Mega Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mega Lifesciences Public's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mega Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mega Lifesciences Public based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Mega Stock
Mega Lifesciences financial ratios help investors to determine whether Mega Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mega with respect to the benefits of owning Mega Lifesciences security.